Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Pharmacyclics Shares Surge on Drug Approval Application

Pharmacyclics Inc. surged to its highest value ever after filing for U.S. approval of a blood cancer drug that is being developed with Johnson & Johnson.

Pharmacyclics climbed 12 percent to $100.26 at 4 p.m. in New York, the highest price since the shares began trading Oct. 25, 1995. The medicine was submitted as a “breakthrough therapy,” which is designed to speed approval, the company said in a statement today.

The filing asks the Food and Drug Administration to clear the Sunnyvale, California-based company’s therapy, ibrutinib, for treatment on two types of lymphoma. Pharmacyclics had said it would submit the application by the end of the third quarter, and seeking two indications was unexpected, Michael King, an analyst at JMP Group Inc. in New York, said in a research note.

“We predict the drug is on the market before the end of this calendar year,” Michael Yee, an analyst with RBC Capital Markets in San Francisco, said in a research note. Such an approval would put the drug at least a year ahead of a possible competitor from Gilead Sciences Inc. and two years ahead of one from AbbVie Inc., he said.

FDA approval is being sought for ibrutinib as a therapy for mantle cell lymphoma as well as chronic lymphomatic leukemia/small lymphocytic lymphoma, an indication the analysts said wasn’t anticipated yet. In February, the FDA gave the drug “breakthrough” status for mantle cell.

Ibrutinib blocks an enzyme called Bruton’s tyrosine kinase that aids certain cancers in spreading.

Johnson & Johnson, based in New Brunswick, New Jersey, gained less than 1 percent to $89.03.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.